SIDE-BY-SIDE
Comparing Three GHRH Analogs
Same upstream mechanism, very different clinical histories — here is how sermorelin, CJC-1295, and tesamorelin actually differ.
The short version
All three compounds on this desk bind the same receptor and activate the same signaling pathway — the GHRH receptor on pituitary somatotrophs, driving pulsatile growth hormone release. Where they diverge is in structure, pharmacokinetics, regulatory history, and the depth of the human evidence. A GHRH analog is simply a synthetic molecule that resembles and mimics the natural signaling peptide. The differences in how each was engineered have large downstream effects on how long it acts and how it has been studied.
This comparison page sets those differences side by side. Use the table as a navigation aid; each compound page has the full evidence detail.
Three GHRH Analogs at a Glance
| Sermorelin | CJC-1295 | Tesamorelin | |
|---|---|---|---|
| Structural basis | GHRH(1-29)NH2 — shortest fully active GHRH fragment | Tetrasubstituted hGRF(1-29); DAC variant adds albumin-binding moiety | Full GHRH(1-44)NH2 with trans-3-hexenoyl N-terminal modification |
| Primary mechanism | GHRH receptor agonist; pulsatile GH/IGF-1 stimulation | GHRH receptor agonist; sustained multi-day GH/IGF-1 elevation (DAC form) | GHRH receptor agonist; pulsatile GH/IGF-1 stimulation; preferential visceral lipolysis |
| Duration of action | Short (minutes to hours) | DAC form: half-life 5.8–8.1 days; no-DAC form: hours | Hours per dose (daily injection in trials) |
| What it is mainly studied for | Pediatric GH deficiency (historical); adult GH insufficiency; endogenous-GH stimulation | GH/IGF-1 pharmacokinetics; endurance/body-composition community interest | HIV-associated lipodystrophy (visceral fat + hepatic fat); endogenous-GH stimulation |
| Evidence maturity | Moderate: human PK studies, pediatric GH-deficiency RCTs, editorial debate on adult use | Low: small early PK studies in healthy adults; discontinued Phase 2 | Strong (within approved indication): multiple Phase 3 RCTs, meta-analysis |
| Regulatory status | Formerly FDA-approved as Geref (NDA 020443, withdrawn 2008 for commercial reasons); now 503A Category 1 compounding | Never approved; not recommended for 503A compounding bulks list (PCAC, 2024) | FDA-approved NDA 022505 (2010) for HIV-associated lipodystrophy only; all else off-label |
| WADA status | Prohibited at all times (S2: hormone and metabolic modulators) | Prohibited at all times (S2) | Prohibited at all times (S2) |
| Key limitation | Long-term adult efficacy and safety trials do not exist; anti-aging claims outpace evidence | No approved indication; thin human data; discontinued development program | Approved indication is narrow; fat reaccumulates on discontinuation; non-HIV generalizability unestablished |
Reading the regulatory differences
The regulatory trajectories of these three compounds are worth slowing down on, because they are frequently conflated in online discussions.
Sermorelin has an unusual history: it was a real approved drug for a specific pediatric indication, then withdrawn from the US market in 2008 by its manufacturer for commercial (not safety) reasons. That history gives it a pharmacological and regulatory documentation that pure research chemicals lack — but it does not mean that its contemporary wellness and anti-aging uses are backed by the same evidence that earned the original approval. The approved use was in growth-hormone-deficient children. Adults interested in it today are using it off-label, in a context where the controlled-trial evidence is limited and a prominent clinical editorial called GH-secretagogue anti-aging use 'not yet ready for prime time' [3].
CJC-1295 went the other direction: into Phase 2 development, then out. The FDA's 2024 PCAC review explicitly declined to recommend it for 503A compounding, citing safety concerns including immunogenicity. It has never been approved anywhere. The human evidence base consists of a handful of pharmacokinetic studies. Its widespread circulation in research communities rests on an extrapolation from pharmacokinetic data to clinical benefit that has never been tested in adequate trials.
Tesamorelin is the exception: a completed drug development program with Phase 3 data and a regulatory decision. Its approval is real — but its scope is narrow. The FDA approved it for HIV-associated lipodystrophy. Claims about its effects in non-HIV populations, healthy aging, or other metabolic contexts are extrapolations from the approved evidence, not established findings.
What the shared mechanism does — and does not — unify
Because all three bind the same receptor and stimulate endogenous GH, it might seem reasonable to extrapolate from tesamorelin's visceral-fat evidence to expectations about sermorelin or CJC-1295. That extrapolation has real mechanistic logic — all three raise GH and IGF-1 — but it is still extrapolation, not evidence.
The Phase 3 tesamorelin trials were conducted in a specific population with a specific pathology (HIV-associated lipodystrophy), under controlled conditions with defined dosing regimens and rigorous endpoints. Applying those results to healthy adults seeking fat loss or body composition improvements — without HIV, without lipodystrophy, and using a different compound — involves multiple inferential steps that the published literature does not close.
This is not a reason to dismiss the mechanism. It is a reason to be specific about what the evidence actually establishes and what it does not. See the individual compound pages for the full detail: Sermorelin, CJC-1295, Tesamorelin.